Skip to main content
Fig. 1 | Cancer & Metabolism

Fig. 1

From: ETV4/ALYREF-mediated glycolytic metabolism through PKM2 enhances resistance to ferroptosis and promotes the development of intrahepatic cholangiocarcinoma

Fig. 1Fig. 1

ETV4 and PKM2 enhance ICC cell proliferation and glycolytic metabolism. (A) High expression levels of ETV4 and PKM2 in ICC were analyzed using the TCGA database. (B) The analysis of the survival rate in the presence of ETV4 and PKM2. (C) The expression levels of ETV4 and PKM2 were detected by WB. (D) Cell proliferation was measured by CCK-8 assay. (E) ICC cell proliferation was detected by the EdU assay (Magnification: ×50, scale bar = 200 μm). (F) Cell migration of ICC cells was assessed by Transwell assay (Magnification: ×100, scale bar = 100 μm). (G-I) Measurement of the GLU, LD, and ATP content in ICC cells. (J) Expression of PDK1, LDHA, and GLUT1 was assessed by WB. (K) Bioinformatics prediction of binding sites between ETV4 and PKM2. (L) ChIP validation of the binding of ETV4 and the promoter of ALYREF. *P < 0.05; **P < 0.01; ***P < 0.001; n = 3

Back to article page

Cancer & Metabolism

ISSN: 2049-3002